46 citations
,
March 2001 in “Journal of endocrinological investigation”
5α-reductaseinhibitors, like finasteride and dutasteride, effectively treat BPH, male baldness, and hirsutism, with potential for acne and prostate cancer prevention.
The conversation concludes that finasteride, a 5α-Reductaseinhibitor used for hair loss, does not impair cognition either short-term or long-term. It suggests "brain fog" is not caused by the medication.
FCE 28260 (PNU 156765), an under-explored 5α-reductaseinhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.
Finasteride and dutasteride, used for hair loss, can cause sexual dysfunction, depression, and suicidal thoughts, with some effects persisting after stopping. The post stresses the importance of being aware of these risks.
The post is a humorous take on the author's experience with hair loss and using finasteride for six months. The conversation includes discussions about hair loss, treatments like finasteride, and personal experiences with baldness.